A combination of omega 3 supplements and low dose aspirin performed about as well as a standard antibiotic regimen in patients with severe gum disease, according to a year long randomized trial published in May in the Journal of Periodontology. About 58 percent of patients treated with antibiotics reached the study's clinical target. In the omega-3 and aspirin group, 57.7 percent did.
Both substantially outperformed the comparison group. Among patients who received the standard deep cleaning plus placebo capsules, only 23.1 percent met the same goal.
The finding is early and the trial is small, at 109 patients. It does not change dental practice today. What it does is open a question that matters for patients who cannot take antibiotics and for a broader problem in medicine, which is how to preserve antibiotics for the infections that have no alternative.
Two Treatments, Nearly Identical Results
The trial was conducted by researchers affiliated with Albert Einstein Israelite Hospital, Guarulhos University, the University of Taubaté, and the Ribeirão Preto School of Dentistry at the University of São Paulo in Brazil, together with Harvard University. It was funded by the São Paulo Research Foundation.
Every participant received subgingival instrumentation, the deep cleaning below the gumline that is standard treatment for periodontitis. The four groups differed only in what came next. One received placebo capsules matching the active treatments. One received metronidazole and amoxicillin three times daily for 14 days. One received three grams of omega-3 daily plus 100 milligrams of aspirin daily for six months. The fourth received both regimens.
Patients were reassessed at three, six, and twelve months. The clinical target was having no more than four remaining periodontal pockets measuring at least 5 millimeters deep. The trial is published in the Journal of Periodontology, and the funder's account of the work is available through its news agency.
Adding antibiotics on top of omega-3 and aspirin produced no additional benefit over either approach alone, a result the researchers described as surprising. Benefits in the supplement group also persisted six months after supplementation stopped.
Antibiotic Resistance Is the Bigger Prize
Severe periodontitis is a chronic inflammatory disease driven by bacteria accumulating below the gumline. In advanced cases it destroys the bone supporting the teeth and can end in tooth loss. Deep pockets act as bacterial reservoirs, which is why the condition is difficult to treat.
Omega 3 works differently from a conventional anti inflammatory. Rather than blocking an inflammatory pathway, it contributes to the production of molecules that help the body resolve inflammation and repair tissue. Low-dose aspirin was added because it can enhance production of those same resolving molecules.
First author Nídia Cristina Castro dos Santos, a professor and researcher at Albert Einstein Israelite Hospital in São Paulo, said the outcome was not what the team expected. "The result was surprising because the two therapies performed very similarly," she said. She also cautioned that antibiotics are not the gold standard for this condition and that their use should be weighed case by case given resistance risks and possible side effects.
Study author Magda Feres, a professor at the Harvard School of Dental Medicine, framed the practical value in terms of patients who have no antibiotic option, saying the combination is "opening up a real alternative for those who can't take antibiotics." She connected the result to a wider concern, arguing that treating severe periodontitis by modulating the body's own response helps preserve antibiotics for cases where they are indispensable. The World Health Organization classifies antimicrobial resistance as one of the leading global public health threats.
Reading the Trial's Fine Print
This was a randomized, double blind, placebo controlled, multicenter trial with a year of follow up, which is a strong design for this field. It is also a single trial with 109 participants, split across four arms, meaning roughly 27 people per group.
The trial enrolled a selected population of adults with advanced periodontitis. That is a meaningful limitation, because the patients most likely to be offered an antibiotic-sparing option in real practice often have other medical conditions. The researchers say additional studies are needed in broader and more diverse populations, and to determine which patients benefit most from which strategy.
Aspirin is not a benign supplement. Daily low dose aspirin carries bleeding risk, and guidance on its routine use has tightened considerably in recent years. The U.S. Preventive Services Task Force recommends against starting low-dose aspirin for primary cardiovascular prevention in adults 60 and older. High-dose omega-3 also has documented interactions and has been associated with atrial fibrillation risk in some trials.
Nobody should start either on the basis of this study. The researchers describe the result as cautious optimism rather than a change in standard care, noting that routine replacement of antibiotics will require more evidence.
Conversations Worth Having With a Dentist
Patients already diagnosed with periodontitis have a reasonable question to raise at their next appointment, particularly those with a documented penicillin or metronidazole allergy or a history of antibiotic intolerance. Asking whether an anti-inflammatory approach has been considered is different from requesting it.
Anyone taking a blood thinner, with a bleeding disorder, a history of ulcers, or an upcoming surgery should be explicit about that before any aspirin discussion. Patients on other medications should ask a pharmacist about interactions with high-dose fish oil. The caution mirrors the evidence on other widely used preventive drugs, including what a large statin trial in older adults did and did not show.
The prevention side has not changed. Bleeding gums, persistent bad breath, gum recession and loose teeth warrant a dental evaluation rather than a supplement purchase. Severe periodontitis diagnosed early is far more treatable than periodontitis diagnosed after bone loss.
Cost is a real barrier here. Many dental plans cap annual benefits well below the price of a full course of periodontal therapy, and deep cleaning is often billed by quadrant. Patients facing that gap can ask about dental school clinics, community health centers with dental services, and payment plans, all of which typically cost less than a private practice course of treatment.
Larger trials in more representative populations are the next step. Until those exist, deep cleaning remains the foundation of treatment and antibiotics remain a case by case decision made with a dentist or periodontist.
Key Questions Answered
What did the trial find? About 58 percent of patients on antibiotics and 57.7 percent on omega 3 plus low dose aspirin reached the clinical target after one year. Only 23.1 percent of the placebo group did.
How large was the study? It enrolled 109 people with advanced periodontitis, split across four groups, and followed them for 12 months with assessments at three, six and twelve months.
Did combining both approaches work better? No. Taking antibiotics alongside omega 3 and aspirin produced no additional benefit over either strategy used alone, which the researchers described as an unexpected result.
Should patients start taking omega-3 and aspirin for gum disease? No. This is one trial in a selected population, and the researchers explicitly say routine replacement of antibiotics will require more evidence. Both substances carry real risks.
What are the risks of daily low-dose aspirin? Bleeding is the main one. Federal guidance recommends against starting low-dose aspirin for primary cardiovascular prevention in adults 60 and older. It should not be started without clinician input.
Who might benefit most if this holds up? Patients who cannot take metronidazole and amoxicillin because of allergy or intolerance, according to the study's authors.
Why does this matter beyond dentistry? Reducing unnecessary antibiotic use is a recognized global public health priority. Antimicrobial resistance is classified by the World Health Organization as a leading threat.
